ZOETIS INC.
ZTSZoetis Inc. (ZTS) is a global leader in animal health, providing a wide range of pharmaceutical, vaccine, and diagnostic products for livestock and companion animals. Established in 1952 and becoming an independent company in 2013, Zoetis develops innovative solutions to improve animal health and well-being, supporting the needs of veterinarians, pet owners, and livestock producers worldwide.
Dividend History
Investors can expect a dividend payout of $0.53 per share, scheduled to be distributed in 45 days on September 1, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 1, 2026 | $0.53 | 2026-07-20 | 2026-07-20 |
| June 2, 2026 | $0.53 | 2026-04-20 | 2026-04-20 |
| March 3, 2026 | $0.53 | 2026-01-20 | 2026-01-20 |
| December 2, 2025 | $0.50 | 2025-10-31 | 2025-10-31 |
| September 3, 2025 | $0.50 | 2025-07-18 | 2025-07-18 |
Dividends Summary
- Consistent Payer: ZOETIS INC. has rewarded shareholders with 54 dividend payments over the past 13 years.
- Total Returned Value: Investors who held ZTS shares during this period received a total of $12.70 per share in dividend income.
- Latest Payout: The most recent dividend of $0.53/share was paid 46 days ago, on June 2, 2026.
- Yield & Schedule: ZTS currently pays dividends quarterly with an annual yield of 2.73%.
- Dividend Growth: Since 2013, the dividend payout has grown by 715.4%, from $0.07 to $0.53.
- Dividend Reliability: ZTS has maintained or increased its dividend for 52 consecutive payments.
Company News
A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during the period of January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its flagship products Librela, Simparica Trio, and ...
A class action lawsuit has been filed against Zoetis Inc. alleging securities fraud for making materially false statements about product growth and market positioning. The complaint claims the company failed to disclose weakening adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Tri...
Zoetis Inc. faces a securities class action lawsuit covering January 14, 2025 through May 6, 2026, with CEO Kristin Peck and CFO Wetteny Joseph named as individual defendants. The lawsuit alleges they certified misleading statements about companion animal product performance while safety concerns and competitive losses mounted. Zoetis shares fell...
The veterinary lab automation market is experiencing robust growth, expanding from $1.26 billion in 2025 to $1.36 billion in 2026 at an 8.4% CAGR, with projections to reach $1.9 billion by 2030. Growth is driven by rising demand for rapid diagnostics, AI integration, companion animal care expansion, and robotic workflow adoption. North America le...
Rosen Law Firm is notifying Zoetis Inc. investors who purchased securities between January 14, 2025 and May 6, 2026 of an important July 27, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Zoetis made false statements about market share and sales growth while failing to disclose weakening adoption of f...
